Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, female health-care products specialist Hologic (Nasdaq: HOLX) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Hologic's business and see what CAPS investors are saying about the stock right now.

Hologic facts

Headquarters (Founded) Bedford, Mass. (1985)
Market Cap $5.5 billion
Industry Health-care equipment
Trailing-12-Month Revenue $1.8 billion
Management CEO Robert Cascella (since 2009)
CFO Glenn Muir (since 1992)
Return on Equity (Average, Past 3 Years) (8.9%)
Cash/Debt $793.1 million / $1.5 billion
Competitors GE Healthcare
Philips Healthcare
Siemens Healthcare

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 716 members who have rated Hologic believe the stock will outperform the S&P 500 going forward.  

Just last week, one of those Fools, toaoyoda, nicely summed up the bull case for our community:

This [women's health] specialist will benefit from increased emphasis on health in general and womens health, in particular. ... It is pre-eminent in the Liquid Based Pap test arena which is supplanting the classical Pap test and being extended throughout the world as women's rights increase in much of the … third world. It is also the leader in digital mammography and specialized surgical procedures.

What do you think about Hologic, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.